Imaflex Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Imaflex ha aumentado sus beneficios a una tasa media anual de 9%, mientras que los beneficios de la industria de Packaging han experimentado un crecimiento de 5.9% anual. Los ingresos han ido creciendo a una tasa media de 4.9% al año. La rentabilidad financiera de Imaflex es de 2.5%, y sus márgenes netos son de 1.5%.

Información clave

9.0%

Tasa de crecimiento de los beneficios

8.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Packaging	6.1%
Tasa de crecimiento de los ingresos	4.9%
Rentabilidad financiera	2.5%
Margen neto	1.5%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

Jun 05

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Jun 10

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

Jun 03

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Apr 19

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Mar 30

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Mar 01

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Feb 04

Is Imaflex (CVE:IFX) A Risky Investment?

Jan 17

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Dec 30

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Dec 15

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Nov 30

What Does Imaflex's (CVE:IFX) CEO Pay Reveal?

Nov 26

Desglose de ingresos y gastos

Cómo gana y gasta dinero Imaflex. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

TSXV:IFX Ingresos, gastos y beneficios (CAD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Mar 24	98	1	8
31 Dec 23	94	1	8
30 Sep 23	92	2	9
30 Jun 23	96	5	8
31 Mar 23	104	8	8
31 Dec 22	112	9	8
30 Sep 22	115	10	8
30 Jun 22	118	10	8
31 Mar 22	114	8	7
31 Dec 21	107	8	7
30 Sep 21	104	8	7
30 Jun 21	97	7	7
31 Mar 21	91	5	7
31 Dec 20	87	6	7
30 Sep 20	83	5	7
30 Jun 20	80	4	7
31 Mar 20	80	4	7
31 Dec 19	81	2	7
30 Sep 19	85	2	7
30 Jun 19	87	2	7
31 Mar 19	88	2	6
31 Dec 18	86	4	6
30 Sep 18	85	4	7
30 Jun 18	85	4	7
31 Mar 18	87	4	7
31 Dec 17	88	4	7
30 Sep 17	86	3	7
30 Jun 17	82	3	7
31 Mar 17	76	2	7
31 Dec 16	74	0	6
30 Sep 16	72	1	6
30 Jun 16	72	1	6
31 Mar 16	73	1	6
31 Dec 15	69	1	6
30 Sep 15	68	1	6
30 Jun 15	66	0	6
31 Mar 15	62	0	5
31 Dec 14	61	0	5
30 Sep 14	59	0	5
30 Jun 14	59	-1	5
31 Mar 14	58	0	5
31 Dec 13	56	0	5
30 Sep 13	54	0	5
30 Jun 13	50	0	5

Ingresos de calidad: IFX tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio(2.2%) de IFX son inferiores a los del año pasado (8.9%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de IFX han crecido un 14.6% al año en los últimos 5 años.

Acelerando crecimiento: IFX ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: IFX tuvo un crecimiento negativo de los beneficios (-80.4%) durante el año pasado, lo que dificulta la comparación con la media de la industria Packaging (-14.9%).

Imaflex Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

First quarter 2024 earnings released: EPS: CA$0.04 (vs CA$0.018 in 1Q 2023)

Full year 2023 earnings released: EPS: CA$0.01 (vs CA$0.18 in FY 2022)

Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.06 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.066 in 2Q 2022)

First quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.04 in 1Q 2022)

Recent updates

Revenues Not Telling The Story For Imaflex Inc. (CVE:IFX) After Shares Rise 48%

Investor sentiment improves as stock rises 18%

There May Be Some Bright Spots In Imaflex's (CVE:IFX) Earnings

First quarter 2024 earnings released: EPS: CA$0.04 (vs CA$0.018 in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: EPS: CA$0.01 (vs CA$0.18 in FY 2022)

Imaflex Inc., Annual General Meeting, Jun 13, 2024

Imaflex (CVE:IFX) Might Be Having Difficulty Using Its Capital Effectively

Third quarter 2023 earnings released: EPS: CA$0.003 (vs CA$0.06 in 3Q 2022)

Is Imaflex (CVE:IFX) A Risky Investment?

Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.066 in 2Q 2022)

Investor sentiment deteriorates as stock falls 18%

Insider recently sold CA$67k worth of stock

Imaflex Inc. Announces CEO Changes

Imaflex Inc. Appoints Roger Tambay as CEO

First quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.04 in 1Q 2022)

Imaflex Inc. Announces Chief Financial Officer Changes

Does Imaflex (CVE:IFX) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: CA$0.18 (vs CA$0.17 in FY 2021)

We Think Imaflex (CVE:IFX) Can Stay On Top Of Its Debt

Third quarter 2022 earnings released: EPS: CA$0.06 (vs CA$0.055 in 3Q 2021)

Imaflex Inc. Provides Earnings Guidance for the Full Year 2022

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Submits Advaseal® Registration Package to the EPA

Does Imaflex (CVE:IFX) Have A Healthy Balance Sheet?

Second quarter 2022 earnings released: EPS: CA$0.07 (vs CA$0.04 in 2Q 2021)

VP of Manufacturing recently sold CA$56k worth of stock

First quarter 2022 earnings released: EPS: CA$0.04 (vs CA$0.039 in 1Q 2021)

Is It Too Late To Consider Buying Imaflex Inc. (CVE:IFX)?

Price target increased to CA$1.95

Insufficient new directors

Imaflex Inc. Provides Earnings Guidance for the First Quarter 2022

Full year 2021 earnings released: EPS: CA$0.17 (vs CA$0.13 in FY 2020)

Imaflex Inc., Annual General Meeting, Jun 16, 2022

Imaflex Inc. Appoints Roberto Longo as Director, Chair the Audit Committee

Imaflex Inc. Announces Resignation of Mario Settino as Director

Vice-President of Corporate Affairs recently sold CA$56k worth of stock

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

Imaflex (CVE:IFX) Could Easily Take On More Debt

Insider recently sold CA$520k worth of stock

VP of Manufacturing recently sold CA$98k worth of stock

Insider exercised options to buy CA$540k worth of stock.

Investors Should Be Encouraged By Imaflex's (CVE:IFX) Returns On Capital

Vice-President of Corporate Affairs exercised options to buy CA$735k worth of stock.

Second quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.007 in 2Q 2020)

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Imaflex Inc.'s (CVE:IFX) CEO For Now

Imaflex (CVE:IFX) Seems To Use Debt Rather Sparingly

First quarter 2021 earnings released: EPS CA$0.039 (vs CA$0.062 in 1Q 2020)

Here's Why I Think Imaflex (CVE:IFX) Might Deserve Your Attention Today

Full year 2020 earnings released: EPS CA$0.13 (vs CA$0.031 in FY 2019)

Investor sentiment improved over the past week

Imaflex (CVE:IFX) Shareholders Will Want The ROCE Trajectory To Continue

Did Imaflex Inc. (CVE:IFX) Insiders Sell Shares?

Is Imaflex Inc.'s (CVE:IFX) Latest Stock Performance A Reflection Of Its Financial Health?

Imaflex Announces Positive Independent Results for the ADVASEAL Release Study

New 90-day high: CA$1.22

Is Imaflex (CVE:IFX) A Risky Investment?

What We Make Of Imaflex's (CVE:IFX) Returns On Capital

Imaflex (CVE:IFX) Is Growing Earnings But Are They A Good Guide?

Have Insiders Sold Imaflex Inc. (CVE:IFX) Shares Recently?

Insider recently sold CA$108k worth of stock

Revenue beats expectations

Imaflex Inc. Updates on Its ADVASEAL Study

What Does Imaflex's (CVE:IFX) CEO Pay Reveal?

New 90-day high: CA$0.78

New 90-day high: CA$0.77

Price target lowered to CA$0.90

First half earnings released